Scientists have discovered that the peptide hormone adrenomedullin plays a pivotal role in obesity-related type 2 diabetes, ...
Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.
The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 ...
The hormone triggers insulin resistance in blood vessel endothelium in obesityA large proportion of the approximately six ...
Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback